| __timestamp | CRISPR Therapeutics AG | Viking Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1513000 | 22223073 |
| Thursday, January 1, 2015 | 12573000 | 6966842 |
| Friday, January 1, 2016 | 42238000 | 9000499 |
| Sunday, January 1, 2017 | 69800000 | 13741186 |
| Monday, January 1, 2018 | 113773000 | 19040000 |
| Tuesday, January 1, 2019 | 179362000 | 23559000 |
| Wednesday, January 1, 2020 | 266946000 | 31931000 |
| Friday, January 1, 2021 | 438633000 | 44981000 |
| Saturday, January 1, 2022 | 461645000 | 54234000 |
| Sunday, January 1, 2023 | 387332000 | 63806000 |
| Monday, January 1, 2024 | 320653000 |
Igniting the spark of knowledge
In the dynamic world of biotechnology, innovation is the lifeblood of progress. Over the past decade, CRISPR Therapeutics AG and Viking Therapeutics, Inc. have been at the forefront of this innovation race. From 2014 to 2023, CRISPR Therapeutics consistently outpaced Viking Therapeutics in research and development (R&D) investments, with an average annual expenditure nearly seven times higher. In 2022, CRISPR Therapeutics peaked with R&D expenses reaching 462 million, while Viking Therapeutics steadily increased its investment, culminating in a 64 million spend in 2023. This trend highlights CRISPR's aggressive pursuit of cutting-edge gene-editing technologies, while Viking focuses on strategic growth in therapeutic development. As the biotech landscape evolves, these investments underscore the companies' commitment to pioneering advancements that could redefine healthcare.
R&D Insights: How Biogen Inc. and CRISPR Therapeutics AG Allocate Funds
Comparing Innovation Spending: United Therapeutics Corporation and Viking Therapeutics, Inc.
Research and Development Expenses Breakdown: Neurocrine Biosciences, Inc. vs Viking Therapeutics, Inc.
Comparing Innovation Spending: Exelixis, Inc. and Viking Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Viking Therapeutics, Inc. and CRISPR Therapeutics AG
Analyzing R&D Budgets: Viking Therapeutics, Inc. vs Supernus Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Viking Therapeutics, Inc. and Protagonist Therapeutics, Inc.
Research and Development Investment: Viking Therapeutics, Inc. vs Dynavax Technologies Corporation
Comparing Innovation Spending: Viking Therapeutics, Inc. and Celldex Therapeutics, Inc.
Research and Development Expenses Breakdown: CRISPR Therapeutics AG vs Arrowhead Pharmaceuticals, Inc.
Comparing Innovation Spending: CRISPR Therapeutics AG and Ligand Pharmaceuticals Incorporated
R&D Spending Showdown: CRISPR Therapeutics AG vs Dynavax Technologies Corporation